Psychometric properties of spanish version of mystical experience questionnaire and wellbeing measures
##plugins.themes.bootstrap3.article.main##
##plugins.themes.bootstrap3.article.sidebar##
https://orcid.org/0000-0001-7932-6772
Abstract
Recent research into psychedelics has found them to be an effective treatment for disorders related to depression, anxiety, and post traumatic stress disorder. Mystical experiences have proven to mediate the therapeutic effects for outcomes; however, Spanish measures have not been studied thoroughly. In this study we explored the psychometric properties of the Mystical Experience Questionnaire (MEQ), Acceptance and Action Questionnaire-II (AAQ-II), and VanderWeele’s Flourishing Measure in a Spanish-speaking sample in Puerto Rico. The MEQ is a 30-item questionnaire that measures the degree of a mystical experience. A total of 235 participants took part in a survey where they answered the MEQ and other well-being questionnaires concerning past or future psychedelic use. For psychometric analysis, 207 participant answers were used for Exploratory Factor Analysis (EFA) and internal consistency. EFA revealed a three-factor structure explaining 65.46% of the variance and displayed high internal consistency for each scale (whole scale McDonald’s ωt=.98) of the MEQ. Furthermore, other well-being scales also displayed high internal consistency. The Spanish translation of the MEQ and other well-being scales demonstrated to be appropriate measures for the assessment of mystical experiences, psychological flexibility, and flourishing in a Spanish-speaking sample with and without the use of psychedelics.
Article Metrics Graph
##plugins.themes.bootstrap3.article.details##
psychedelics, mystical experience, psychometry, well-being
Bossis, A. P. (2021). Utility of Psychedelics in the Treatment of Psychospiritual and Existential Distress in Palliative Care: A Promising Therapeutic Paradigm. In C. S. Grob & J. Grigsby (Eds.), Handbook of Medical Hallucinogens. Guilford Press.
Bouso, J. C., Pedrero-Pérez, E. J., Gandy, S., & Alcázar-Córcoles, M. Á. (2016). Measuring the subjective: revisiting the psychometric properties of three rating scales that assess the acute effects of hallucinogens. Human Psychopharma-cology: Clinical and Experimental.
https://doi.org/10.1002/hup.2545
Carhart-Harris, R., Giribaldi, B., Watts, R., Baker-Jones, M., Murphy-Beiner, A., Murphy, R., Martell, J., Blemings, A., Erritzoe, D., & Nutt, D. J. (2021). Trial of Psilocybin versus Escitalopram for Depression. New England Journal of Medicine, 384(15), 1402–1411.
https://doi.org/10.1056/nejmoa2032994
Davis, A. K., Timmermann, C., Ortiz Bernal, A. M., Lancelotta, R., Nayak, S., Sepeda, N. D., Nikolaidis, A., & Griffiths, R. R. (2023). Translation and Initial Psycho-metric Evaluation of Spanish Versions of Three Psychedelic Acute Effects Measures: Mystical, Challenging, and Insight Experiences. Journal of Psychoactive Drugs.
https://doi.org/10.1080/02791072.2023.2232379
Franenkel, J., & Wallen, N. (2009). How to Design and Evaluate Research in Education (Seventh Ed). McGraw-Hill.
Griffiths, R. R., Johnson, M. W., Richards, W. A., Richards, B. D., McCann, U., & Jesse, R. (2011). Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects. Psychopharmacology, 218(4), 649–665. https://doi.org/10.1007/s00213-011-2358-5
Griffiths, R. R., Richards, W. A., Johnson, M. W., McCann, U. D., & Jesse, R. (2008). Mystical-type experiences occasioned by psilocybin mediate the attribution of personal meaning and spiritual significance 14 months later. Journal of Psychopharmacology, 22(6), 621–632. https://doi.org/10.1177/0269881108094300
Griffiths, R. R., Richards, W. A., McCann, U., & Jesse, R. (2006). Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual signifi-cance. Psychopharmacology, 187(3), 268–283.
https://doi.org/10.1007/s00213-006-0457-5
MacLean, K. A., Leoutsakos, J. M. S., Johnson, M. W., & Griffiths, R. R. (2012). Factor Analysis of the Mystical Experi-ence Questionnaire: A Study of Experi-ences Occasioned by the Hallucinogen Psilocybin. Journal for the Scientific Study of Religion, 51(4), 721–737. https://doi.org/10.1111/j.1468-5906.2012.01685.x
Nichols, D. E., & Nichols, C. D. (2021). The Pharmacology of Psychedelics. In C. S. Grob & J. Grigsby (Eds.), Handbook of Medical Hallucinogens. Guilford Press.
Passie, T. (2021). History of the Use of Hallucinogens in Psychiatric Treatment. In C. S. Grob & J. Grigsby (Eds.), Handbook of Medical Hallucinogens2. Guilford Press.
Ross, S., Bossis, A., Guss, J., Agin-Liebes, G., Malone, T., Cohen, B., Mennenga, S. E., Belser, A., Kalliontzi, K., Babb, J., Su, Z., Corby, P., & Schmidt, B. L. (2016). Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: A randomized con-trolled trial. Journal of Psychopharma-cology, 30(12), 1165–1180.
https://doi.org/10.1177/0269881116675512
Stace, W. T. (1960). Mysticism and philosophy. The MacMillan Press.
VanderWeele, T. J. (2017). On the promotion of human flourishing. Proceedings of the National Academy of Sciences of the United States of America, 114(31), 8148–8156. https://doi.org/10.1073/pnas.1702996114
Wȩziak-Białowolska, D., McNeely, E., & VanderWeele, T. J. (2019). Human flourishing in cross cultural settings. Evidence from the United States, China, Sri Lanka, Cambodia, and Mexico. Frontiers in Psychology, 10(MAY). https://doi.org/10.3389/fpsyg.2019.01269